Insights+: EMA Marketing Authorization of New Drugs in May 2023

Shots:The EMA approved 3 New Chemical Entity (NCE) and 7 Biologic Drugs in May 2023, leading to treatments for patients and advances in the healthcare industryIn May 2023, the major highlights drugs were Breyanzi’s Approval for relapsed or refractory large B-cell lymphoma, Ultomiris (ravulizumab) for neuromyelitis optica spectrum disorderPharmaShots has compiled a…

BySenior EditorJune 26, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023

Shots:The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's DiseasePharmaShots has…

BySenior EditorJune 21, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots:The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industryIn February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndromePharmaShots has compiled…

BySenior EditorMarch 23, 2023

Insights+: EMA Marketing Authorization of New Drugs in May 2023

Insights+: The US FDA New Drug Approvals in May 2023

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Contact US

OUR INFORMATION

FOLLW US

Insights+: EMA Marketing Authorization of New Drugs in May 2023

Insights+: The US FDA New Drug Approvals in May 2023

Insights+: EMA Marketing Authorization of New Drugs in February 2023

FOLLW US

Sign Up to Our Newsletter